Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jack Bartram
A phase 1 feasibility trial of BE-CAR33, an “off-the-shelf” base-edited CAR33 T cell therapy for acute myeloid leukemia
Editor’s summary Abstract INTRODUCTION RESULTS DISCUSSION MATERIALS AND METHODS Acknowledgments Supplementary Materials REFERENCES AND NOTES Information & Authors Metrics & Citations View Options References Figures Tables Media Share Editor’s summary Chimeric antigen receptor (CAR) T cell therapies for acute myeloid leukemia (AML) have not progressed into clinical practice at the same rate as CAR T cells for lymphoid leukemias. Here, Georgiadis et al.
MCL1 inhibition to enhance the efficacy of MYB targeting in pediatric acute myeloid leukemia
Abstract Outcomes for pediatric acute myeloid leukemia (AML) have improved significantly in recent years. However, relapsed and refractory disease remains a significant problem. The chemotherapy burden experienced by these patients makes the translational development of non-genotoxic experimental therapies attractive. We previously reported that the anti-helminth drug mebendazole induces degradation of the transcription factor MYB and has potent anti-AML activity.
Single cell transcriptional evolution of myeloid leukemia of Down syndrome
|
Abstract Children with Down syndrome have a 150-fold increased risk of developing myeloid leukaemia (ML-DS). Unusually for a childhood leukaemia, ML-DS arises from a preleukaemic state, termed transient abnormal myelopoiesis (TAM), via a conserved sequence of mutations. Here, we examine the relationship between the genetic and transcriptional evolution of ML-DS from natural variation; a rich collection of primary patient samples and foetal tissues with a range of constitutional karyotypes.
By Mi K Trinh, Konstantin Schuschel, Hasan Issa, Rebecca Thomas, Conor Parks, Agnes Oszlanczi, Di Zhou, Lira Mamanova, Elena Prigmore, Angus Hodder, Anna Wenger, Nathaniel Anderson, Holly Whitfield Verified, Taryn D Treger, José Gonçalves-Dias, Karin Straathof, David H. O’Connor, Matthew Young Verified, Laura Jardine, Stuart Adams, Jan-Henning Klusmann, Jack Bartram, Sam Behjati, Toochi Ogbonnah, Emilia R. Robertson
|
Nature
Verified
A non-canonical lymphoblast in refractory childhood T-cell leukaemia - Nature Communications
Abstract Refractory cancers may arise either through the acquisition of resistance mechanisms or represent distinct disease states. The origin of childhood T-cell acute lymphoblastic leukaemia (T-ALL) that does not respond to initial treatment, i.e. refractory disease, is unknown. Refractory T-ALL carries a poor prognosis and cannot be predicted at diagnosis. Here, we perform single cell mRNA sequencing of T-ALL from 58 children (84 samples) who did, or did not respond to initial treatment.
B-Cell Acute Lymphoblastic Leukaemia Presenting With Bilateral Renal Enlargement
Specialty Please choose I'm not a medical professional. Allergy and Immunology Anatomy Anesthesiology Biostatistics Cardiac/Thoracic/Vascular Surgery Cardiology Critical Care Dentistry Dermatology Diabetes and Endocrinology Emergency Medicine Epidemiology and Public Health Family Medicine Forensic Medicine Gastroenterology General Practice Genetics Geriatrics Health Policy Hematology HIV/AIDS Hospital-based Medicine I'm not a medical professional.
‘Cutting-edge’ test on NHS dramatically improves cancer care for children
Experts are so delighted with the findings of a new study into the genetic test they believe it could benefit 1,000 children a year in England alone. The test, known as whole genome sequencing and available on the NHS, is quicker at giving results than standard tests and offers more benefits than all of them combined, according to researchers at Great Ormond Street Hospital, the University of Cambridge, Cambridge University Hospitals and the Wellcome Sanger Institute.
Benefits for children with suspected cancer from routine whole-genome sequencing - Nature Medicine
Abstract Clinical whole-genome sequencing (WGS) has been shown to deliver potential benefits to children with cancer and to alter treatment in high-risk patient groups. It remains unknown whether offering WGS to every child with suspected cancer can change patient management.
Clinical application of tumour-in-normal contamination assessment from whole genome sequencing - Nature Communications
Abstract The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing.
Clinical application of tumour-in-normal contamination assessment from whole genome sequencing
Abstract The unexpected contamination of normal samples with tumour cells reduces variant detection sensitivity, compromising downstream analyses in canonical tumour-normal analyses. Leveraging whole-genome sequencing data available at Genomics England, we develop a tool for normal sample contamination assessment, which we validate in silico and against minimal residual disease testing.
Clinical application of tumour in normal contamination assessment from whole genome sequencing
New Results Jonathan Mitchell, Jack Bartram, Susan Walker, Jane Chalker, Magdalena Zarowiecki, Salvatore Milite, Genomics England Research Consortium, Alona Sosinsky, View ORCID ProfileGiulio Caravagna doi: https://doi.org/10.1101/2022.03.09.483623 Abstract Bioinformatics pipelines designed for paired analysis of tumour and matched normal samples use germline variants detected from normal tissue samples to identify bona fide tumour somatic mutations.
Primary immunodeficiencies and their associated risk of malignancies in children: an overview
Abstract Primary immunodeficiency disorders represent a heterogeneous spectrum of diseases, predisposing to recurrent infections, allergy, and autoimmunity. While an association between primary immunodeficiency disorders and increased risk of cancer has been suggested since the 1970s, renewed attention has been given to this topic in the last decade, largely in light of the availability of large registries as well as advances in next generation sequencing.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jack
Contact Jack, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack